Literature DB >> 30656600

Chinese Medicine Shensong Yangxin Capsule () Ameliorates Myocardial Microcirculation Dysfunction in Rabbits with Chronic Myocardial Infarction.

Chan Jiang1,2, Xi Wang3,4, Song Dang1,2, Xin Wang1,2, Qing Deng1,2, Juan Hu1,2, Cong-Xin Huang1,2.   

Abstract

OBJECTIVE: To investigate the effect of Chinese compound Shensong Yangxin Capsule ( , SSYX) on myocardial microcirculation in myocardial-infarcted rabbits.
METHODS: Myocardial infarction (MI) was established in rabbits by ligation of the left circumflex coronary. Thirty rabbits were randomly divided into the control group, the MI group (model), and the MI treated with SSYX group (MI+SSYX) by a random number table method. After 4 weeks of administration, low-energy real-time myocardial contrast echocardiography (RT-MCE) was conducted to assess the microcirculatory perfusion. Immunofluorescence double staining was used to detect the capillary density. The endothelial ultrastructure was observed with a transmission electron microscope. The mRNA expression levels of vascular endothelial growth factor (VEGF), endothelin 1 (ET-1), prostaglandin I2 (PGI2) and endothelial nitric oxide synthase (eNOS) were measured by real-time quantitative polymerase chain reaction (Real-time PCR). The plasmic levels of ET-1, thromboxane A2 (TXA2), nitric oxide (NO) and von willebrand factor (vWF) were examined with enzyme-linked immunosorbent assays (ELISA).
RESULTS: SSYX significantly improved the myocardial blood volume, myocardial micro bubble velocity, and myocardial inflow according to the examination of RT-MCE, and it visibly ameliorated the capillary endothelial structure. Furthermore, compared with the MI group, the plasma levels of TXA2, ET-1 and vWF contents significantly decreased in the MI+SSYX group, and the ET-1 mRNA expression levels of myocardium in the border zone significantly decreased, and the VEGF, PGI2 and eNOS mRNA expression levels significantly increased (all P<0.05).
CONCLUSIONS: SSYX has favorable advantages in ameliorating the impaired myocardial microcirculation following MI. The mechanisms of the effect are related to the ability of SSYX in balancing the endothelial-derived vasodilators and vasoconstrictors, and up-regulating the expression of VEGF and eNOS.

Entities:  

Keywords:  Shensong Yangxin Capsule; angiogenesis; endothelium; microcirculation; myocardial infarction

Year:  2019        PMID: 30656600     DOI: 10.1007/s11655-018-2578-1

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  3 in total

Review 1.  Regulation of coronary blood flow. Effect of coronary artery stenosis.

Authors:  D J Duncker; D Merkus
Journal:  Arch Mal Coeur Vaiss       Date:  2004-12

Review 2.  Shen Song Yang Xin Capsule Combined with Antiarrhythmic Drugs, a New Integrative Medicine Therapy, for the Treatment of Frequent Premature Ventricular Contractions (FPVC): A Meta-Analysis of Randomized Controlled Trials.

Authors:  Jie Wang; Jun Li; Bo Feng
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-18       Impact factor: 2.629

3.  Chinese medicine shensongyangxin is effective for patients with bradycardia: results of a randomized, double-blind, placebo-controlled multicenter trial.

Authors:  Yunfang Liu; Ning Li; Zhenhua Jia; Feng Lu; Jielin Pu
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-16       Impact factor: 2.629

  3 in total
  2 in total

1.  Intervention Effect of Traditional Chinese Medicine Hot Pressing Combined with Health Education on the Adolescent's Visual Fatigue.

Authors:  Yanping Tang; Xiaoxia Wei; Yao Huang; Junying Huang; Weihong Jin; Yanhua Lu; Tan Ge; Ying Tang
Journal:  J Healthc Eng       Date:  2022-03-22       Impact factor: 2.682

Review 2.  Integrating Evidence of the Traditional Chinese Medicine Collateral Disease Theory in Prevention and Treatment of Cardiovascular Continuum.

Authors:  Iokfai Cheang; Shengen Liao; Qingqing Zhu; Gehui Ni; Cong Wei; Zhenhua Jia; Yiling Wu; Xinli Li
Journal:  Front Pharmacol       Date:  2022-03-15       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.